Nerve conduction velocity and H-reflex recovery in bipolar illness

Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia

Multiple lines of evidence in schizophrenia, from brain imaging, studies in postmortem brains, and genetic association studies, have implicated oligodendrocyte and myelin dysfunction in this disease. Recent studies suggest that oligodendrocyte and myelin dysfunction leads to changes in synaptic formation and function, which could lead to cognitive dysfunction, a core symptom of schizophrenia. Furthermore, there is accumulating data linking oligodendrocyte and myelin dysfunction with dopamine and glutamate abnormalities, both of which are found in schizophrenia. These findings implicate oligodendrocyte and myelin dysfunction as a primary change in schizophrenia, not only as secondary consequences of the illness or treatment. Strategies targeting oligodendrocyte and myelin abnormalities could therefore provide therapeutic opportunities for patients suffering from schizophrenia.

Differential response of bipolar and normal control lymphoblastoid cell sodium pump to ethacrynic acid

BACKGROUND

While the pathogenesis of manic-depressive, or bipolar, illness is unknown, an excess of intracellular sodium and calcium concentrations is thought to contribute to the development of the illness. Previous work has demonstrated a reduced adaptive response of the sodium pump to ethacrynic acid in lymphocytes obtained from bipolar subjects compared to psychiatrically normal controls.

METHODS

To further examine this phenomenon, we investigated several aspects of sodium pump response (transcription, translation, activity, and intracellular ion concentration) in lymphoblastoid cell lines derived from bipolar subjects and matched normal controls. Cells were treated with ethacrynic acid 100 microM for 3 days.

RESULTS

Normal control-derived cells exhibited an upregulation of sodium pump mRNA synthesis, protein expression, pump-specific binding and activity, and were able to maintain a normal intracellular sodium concentration. Cells derived from bipolar individuals did not alter sodium pump parameters in any way, and consequently, had a higher intracellular sodium concentration.

LIMITATIONS

While bipolar lymphoblasts were from an inbred Old Order Amish population, the normal controls were from an outbred population.

CONCLUSIONS

The results suggest that bipolar illness is associated with an abnormality in cellular sodium homeostatic regulation.

Action potential conduction speed and dyscorrelation, affective disorders and the influence of essential fatty acids

The endogenous affective disorders have been postulated to be due to the neurotransmitter theories, even though there is increasing evidence of a timing abnormality. Recently, action potential (AP) speed differentials and resulting AP dyscorrelation have been postulated for the bipolar disorders. This AP dyscorrelation path is extended here to include some of the other affective disorders. The genetic studies have confirmed loci and proteins which probably predispose to increased water compartmentalization differentials. Indeed, higher water compartmentalization differentials have been confirmed in affective phenotypes. Electrophysiological measures have consistently suggested AP dyscorrelation in patients and more recently in "unaffected" carriers. Future studies should use genotyped subjects and manipulations to investigate possible manipulation-induced water compartmentalization changes and AP speed changes.

Intracerebroventricular administration of ouabain as a model of mania in rats

BACKGROUND

Human bipolar illness is characterized by mood state- and diagnosis-associated abnormalities of cellular cation distribution and transport. These include reduced sodium pump activity and expression and increased intracellular sodium. If these alterations are related to the pathophysiology of the disease, rather than secondary or ancillary abnormalities, then one would expect that modeling of these changes in vivo would produce lithium-preventable behavioral abnormalities.

METHODS

Ouabain, a potent inhibitor of the sodium pump, was administered intracerebroventricularly to male rats previously fed lithium-containing food or plain rat chow. Locomotion was then quantified in an open field.

RESULTS

Ouabain increased locomotion 300% over baseline. Lithium pretreatment prevented the ouabain-induced hyperlocomotion response.

CONCLUSION

Inhibition of central nervous system sodium pump with ouabain produces a plausible animal model of mania. This model may be useful for preclinical screening of potential mood stabilizers.

Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage

BACKGROUND

The pathophysiology of manic-depression may be associated with dysregulation of ion homeostasis. Ouabain is a potent inhibitor of the sodium-potassium adenosine triphosphatase and has been purported to mimic abnormalities seen in acute mania. As manic episodes are believed to be neurotoxic and mood stabilizers have recently been implicated as neuroprotectants, it is of interest to determine if lithium and valproic acid antagonize ouabain-induced neurotoxicity.

METHODS

Human neuroblastoma SH-SY5Y cells were differentiated for 12 days then pretreated with lithium or valproic acid for 24 h and then challenged with a 10 microM ouabain insult. Cellular damage was assessed with lactate dehydrogenase (LDH) release, and apoptotic potential of ouabain was evaluated with DNA fragmentation.

RESULTS

Ouabain significantly increased LDH release after 72 h of treatment. Lithium pretreatment at 1 mM diminished ouabain-induced LDH release. Valproic acid alone at 100 and 1000 micrograms/mL significantly increased LDH release from the cells. Furthermore, it significantly potentiated ouabain-induced LDH release. DNA fragmentation suggests that ouabain induces apoptosis.

CONCLUSIONS

Lithium at the therapeutic level of 1 mM limits the extent of cellular damage caused by 10 microM ouabain in SH-SY5Y cells as measured by LDH release. Valproic acid alone at the therapeutic concentration of 100 micrograms/mL induces LDH release and does not prevent ouabain-induced LDH release.